Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells.
about
Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmaniaMolecular mechanisms of drug resistance in natural Leishmania populations vary with genetic backgroundExperimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocolTreatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, IndiaImipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infectionOver-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovaniIn vitro susceptibilities of wild and drug resistant leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacyAntimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-β in early immune responseOver-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovaniComparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant StrainEvolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinentIn vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stressDevelopments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Development and comparative evaluation of two antigen detection tests for Visceral Leishmaniasis.Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race.Flavone-resistant Leishmania donovani overexpresses LdMRP2 transporter in the parasite and activates host MRP2 on macrophages to circumvent the flavone-mediated cell death.Host resistance to visceral leishmaniasis: prevalence and prevention.Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.Simple colorimetric trypanothione reductase-based assay for high-throughput screening of drugs against Leishmania intracellular amastigotes.Molecular identification of an old clinical isolate of Indian Kala-azar.Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.Wnt5a Signaling Promotes Host Defense against Leishmania donovani Infection.The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.CE-ESI-MS metabolic fingerprinting of Leishmania resistance to antimony treatment.Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation.Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.Reverse Epidemiology: An Experimental Framework to Drive Biomarker Discovery by Functional Genetic Screening Using Relevant Animal ModelsImportance of secondary screening with clinical isolates for anti-leishmania drug discovery
P2860
Q27009505-BCDA1375-D741-49D8-8B20-28BA2F71F777Q28481297-4B21A170-E0C8-4204-B780-EC7A80FDA8F9Q28483977-6C302D88-FD9B-47B7-A7D2-CA7A5ED0F529Q28484459-366CB310-6888-411F-B421-9E19591D117BQ28484622-5897E120-EC07-498D-B014-FCE3A468331DQ28536134-11687E8E-027E-4C1C-8A67-DDD06F75ACF4Q28536688-9BB43B12-189E-4613-B2EA-F21578C87012Q28540810-6C1C4557-ADB8-4279-84E9-D6365B00CCAEQ28547415-E55A11CD-C670-484C-B839-A7979C8B29B0Q28550306-D87EEF2E-4FD2-4FD7-89B7-B6B51CFF8E3BQ28551055-820A2B5D-BC5F-4D9B-AE7A-422AF4ACBE72Q30380900-89AD1BCB-F576-49AD-AF39-349806AEE151Q33797614-9F559EAD-339F-4EFC-93CE-F5D551864A79Q34328882-BDDCDFAA-EFEB-4ABA-83BB-F9D4C5FE4C37Q36086604-851C9A03-319E-4DB7-A742-961270C60FCEQ36616938-7611FE49-6E0C-4BBF-98CA-24F6857CC34BQ37712969-C63C23A5-3F59-43CF-9099-306BEA24CC7DQ38040818-0568DE8D-1F76-47FF-BF2F-205FDF4C3362Q38118386-F254F721-5E63-461D-A61A-9B725ED2EEF6Q38307939-0195E852-DB0D-4E29-B840-742B633ED63EQ38757973-A801E025-841C-4D6F-ADBC-5DA43F298301Q38904942-D49A22CC-8A35-4F55-811C-CC61FE928DC3Q38904947-F805D5F9-A483-4B05-B5B8-12ED9DA9A6BAQ39067203-A7B7525D-E15B-48B5-B160-1ABE31A0AE8FQ39211481-DA8A5B02-C196-4DBA-B43A-F49186EA24DCQ39226324-8FD1CB00-2B0A-4777-B352-97B89D873300Q40067217-BBB91CD4-1F17-4B94-912F-12E7C44D37F0Q40154462-E96CD0E2-3EC3-44CB-990B-92017A684B31Q40177604-C02D787F-124B-44FD-8831-8F4F617B0F73Q42548785-F1B00C81-E01A-4387-BBAE-47A403B46057Q44020193-BC9A548E-9AFC-45BB-9F52-D0BCE99C33B1Q46581744-F778B9CA-2644-4DBB-9E42-D236AAFEB03AQ52566647-8CAF07EF-9885-4746-84D1-7A9FD6E4FB35Q53120855-0F94001E-AE1E-4320-96FF-4086132A7A00Q57072540-89CA99E8-985C-47D5-A7D8-6284CFF060A7Q57929890-56609917-91F0-4A04-8EB9-9B5E34E2D35D
P2860
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Characterisation of antimony-r ...... d interaction with host cells.
@en
Characterisation of antimony-r ...... d interaction with host cells.
@nl
type
label
Characterisation of antimony-r ...... d interaction with host cells.
@en
Characterisation of antimony-r ...... d interaction with host cells.
@nl
prefLabel
Characterisation of antimony-r ...... d interaction with host cells.
@en
Characterisation of antimony-r ...... d interaction with host cells.
@nl
P2093
P50
P1476
Characterisation of antimony-r ...... d interaction with host cells.
@en
P2093
Bart Ostyn
Jean Claude Dujardin
Kshudiram Naskar
Rupkatha Mukhopadhyay
Sandip Mukherjee
Syamal Roy
P304
P356
10.1016/J.IJPARA.2011.07.013
P577
2011-09-07T00:00:00Z